MICCAI 2021 Presentation
- Neosoma
- Nov 4, 2021
- 1 min read
Updated: Nov 22, 2021
Dr. Aly Abayazeed, Co-Founder and Chief Medical Officer, presented findings from Neosoma's high-grade glioma tumor segmentation architecture under the abstract, "Clinical Translation: Development And Performance Testing Of A Generalizable And Reproducible High-Grade Glioma MRI Segmentation And Volumetric Analysis Deep-Learning Network For Longitudinal Assessment To Clinically Inform The Modified Response Assessment In Neuro-Oncology Criteria"

This abstract (below) and presentation (available through a download link) highlighted Neosoma's high-level NS-HGlio algorithm architectural design and empirical validation results.
Comments